Alterity Therapeutics Ltd
ATHEFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Alterity Therapeutics Ltd Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 9 annual periods. The latest annual period ends Jun 30, 2025. The latest insider filing shown is dated Jun 23, 2026. The latest institutional report shown is dated Jun 30, 2025; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
No 13F rows are listed for Alterity Therapeutics Ltd.
- 5 rows left out: they repeat the same share count and value quarter after quarter, which a market value cannot do.
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-15 | Gozlan Lawrence Bernard · Director | Listed option exp 15 Jun 2031 | A — Grant, award, or other acquisition | +1,000,000 | SEC filing |
| 2026-06-15 | Babarczy Julian Michael · Director | Unlisted option exp 15 Jun 2031 | A — Grant, award, or other acquisition | +2,000,000 | SEC filing |
Showing 2 of 2 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.